WCN2026｜MT1013头对头研究完整数据亮相2026世界肾脏病大会

当地时间3 月 31 日，2026年世界肾脏病大会（WCN）在日本横滨圆满落幕。陕西麦科奥特医药科技股份有限公司自主研发的全球首创双功能肽MT1013，其II期与依特卡肽头对头关键研究（MT1013-II-C03）完整数据以壁报形式向全球肾脏病学界正式公布（壁报编号：WCN26-AB-7392）。研究结果显示，MT1013在综合达标率（血钙、血磷、iPTH）及心血管风险关键指标FGF-23的改善方面均显著优于已上市最优拟钙剂依特卡肽，同时展现出良好的安全性与耐受性。

世界肾脏病大会（WCN）是国际肾脏病学会（ISN）主办的全球最高规格、最具影响力的肾病领域学术盛会，汇聚百余国家地区数千名顶尖专家、学者与研发机构，集中展示肾病领域最前沿基础研究、突破性临床成果与革新性治疗策略，引领全球肾脏疾病诊疗发展。

WCN2026于3月28日—31日在日本横滨隆重召开，由国际肾脏病学会（ISN）、日本肾脏病学会（JSN）、亚太肾脏病学会（APSN）联合主办。本次WCN时隔 36 年重返日本，亚太区域肾科专家参与度更高，发布数据更贴合亚太人群临床需求。

本次发布的MT1013-II-C03研究结果提示，相较于依特卡肽，MT1013实现了更优的：

❶综合达标率显著提升：钙、磷、iPTH三项综合达标率（39.29%与34.48%）是依特卡肽组（15.63%）的约2.2至2.5倍。

❷ 潜在心血管保护获益 ：MT1013两组FGF-23降幅（−33.5%与−39.9%）均优于依特卡肽组（−22.8%）。已有研究表明，FGF-23降幅>30%与心血管死亡风险降低34%、猝死风险降低43%直接相关（Moe et al., Circulation, 2015）。

❸ 良好的安全性与耐受性：MT1013症状性低钙血症发生率(7.69%)低于依特卡肽组（12.125%）。

依特卡肽主要解决“抑制 PTH“ 的单点问题，而 MT1013 通过“调控代谢 + 促骨生成”双通路，从源头修复 CKD-MBD 的代谢紊乱，实现了从“控制病情”到“主动修复”的治疗理念升级。

On March 31 (local time), the World Congress of Nephrology 2026 concluded in Yokohama, Japan. Full data from the pivotal Phase II head-to-head study (MT1013-II-C03) of MT1013—a globally first-in-class bifunctional peptide developed by Shaanxi Micot Pharmaceutical Technology Co., Ltd.—vs. etelcalcetide were presented to the global nephrology community as a poster (No.: WCN26-AB-7392). Results showed MT1013 was superior to the marketed calcimimetic etelcalcetide in composite target attainment (serum calcium, phosphorus, and iPTH) and reduction in the key cardiovascular (CV) risk biomarker FGF-23, with a favorable safety and tolerability profile.

The World Congress of Nephrology（WCN）, hosted by the International Society of Nephrology (ISN), is the most prestigious and influential global nephrology congress. It convenes thousands of leading experts, investigators, and institutions from over 100 countries and regions, showcasing advances in basic research, clinical data, and innovative therapies, and shaping global kidney disease management.

WCN 2026 was held March 28–31 in Yokohama, Japan, co-hosted by the International Society of Nephrology, the Japanese Society of Nephrology, and the Asian Pacific Society of Nephrology. Returning to Japan after 36 years, it saw stronger Asia-Pacific participation, with data more aligned with regional clinical needs.

Results from MT1013-II-C03 showed that vs. etelcalcetide, MT1013 achieved:

❶ Higher composite target attainment rate:Composite control of serum calcium, phosphorus, and iPTH (39.29% and 34.48%) was approximately 2.2–2.5 times that of etelcalcetide (15.63%).

❷ Potential CV benefit:Reduction in FGF-23 in the two MT1013 groups (−33.5% and −39.9%) exceeded that in the etelcalcetide group (−22.8%). Prior studies show that a >30% reduction in FGF-23 is associated with a 34% reduction in CV mortality and a 43% reduction in sudden death risk (Moe et al., Circulation, 2015).

❸ Favorable safety and tolerability profile: The incidence of symptomatic hypocalcemia with MT1013 (7.69%) was lower than that with etelcalcetide (12.125%).

Etelcalcetide primarily addresses “PTH suppression,” whereas MT1013, via dual pathways of metabolic regulation and bone formation, targets the underlying metabolic disturbances of CKD-MBD, enabling a shift from “disease control” to “active correction.”